在未经TKI治疗的EGFR-L858R突变肺腺癌中，新发ERBB2扩增导致对厄洛替尼产生内在抗性。 - Suppr

Suppr

超能文献

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

作者信息

Carney Brian J, Rangachari Deepa, VanderLaan Paul A, Gowen Kyle, Schrock Alexa B, Ali Siraj M, Costa Daniel B

机构信息

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

出版信息

Lung Cancer. 2017 Dec;114:108-110. doi: 10.1016/j.lungcan.2017.08.018. Epub 2017 Aug 24.

DOI:10.1016/j.lungcan.2017.08.018

PMID:28870636

Abstract

摘要

相似文献

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.在未经TKI治疗的EGFR-L858R突变肺腺癌中，新发ERBB2扩增导致对厄洛替尼产生内在抗性。

Lung Cancer. 2017 Dec;114:108-110. doi: 10.1016/j.lungcan.2017.08.018. Epub 2017 Aug 24.

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).西班牙裔人群中表皮生长因子受体突变阳性肺腺癌患者对厄洛替尼获得性耐药（CLICaP）

Target Oncol. 2017 Aug;12(4):513-523. doi: 10.1007/s11523-017-0497-2.

Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.重楼皂苷I通过抑制IL-6/STAT3信号通路克服肺癌细胞中与上皮-间质转化相关的厄洛替尼耐药性。

Biol Pharm Bull. 2017 Aug 1;40(8):1306-1313. doi: 10.1248/bpb.b17-00271. Epub 2017 May 18.

Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.一名未经治疗的肺腺癌患者中酪氨酸激酶抑制剂敏感和耐药的EGFR突变共存及对厄洛替尼的反应

J Thorac Oncol. 2014 Jul;9(7):e55-e57. doi: 10.1097/JTO.0000000000000197.

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.晚期肺腺癌中表皮生长因子受体外显子20插入：临床结果及对厄洛替尼的反应

Cancer. 2015 Sep 15;121(18):3212-3220. doi: 10.1002/cncr.29493. Epub 2015 Jun 10.

Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.吸烟对携带激活型表皮生长因子受体（EGFR）突变的肺腺癌患者表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂治疗反应的影响。

Lung Cancer. 2014 May;84(2):196-202. doi: 10.1016/j.lungcan.2014.01.022. Epub 2014 Feb 3.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.155 例 EGFR 突变型肺癌患者获得性 EGFR-TKI 治疗耐药时的肿瘤标本分析。

Clin Cancer Res. 2013 Apr 15;19(8):2240-7. doi: 10.1158/1078-0432.CCR-12-2246. Epub 2013 Mar 7.

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.基于体积的肿瘤生长动力学作为接受表皮生长因子受体酪氨酸激酶抑制剂治疗的表皮生长因子受体突变型肺腺癌患者的预后生物标志物：一项病例对照研究。

Cancer Imaging. 2016 Mar 16;16:5. doi: 10.1186/s40644-016-0063-7.

Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report.使用基于数字滴度PCR的液体活检实时监测表皮生长因子受体酪氨酸激酶抑制剂耐药性：一例病例报告

J Clin Pathol. 2018 Aug;71(8):754-756. doi: 10.1136/jclinpath-2018-205210. Epub 2018 May 31.

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.肺腺癌初始携带有敏感 EGFR 突变，一线吉非替尼和二线细胞毒化疗获得性耐药。

BMC Pharmacol Toxicol. 2017 May 10;18(1):21. doi: 10.1186/s40360-017-0130-0.

引用本文的文献

TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.TP53 或 CDKN2A/B 共突变与 ALK/RET/ROS1 重排 NSCLC 相关，具有高 TMB、肿瘤免疫抑制微环境和不良预后。

J Cancer Res Clin Oncol. 2023 Sep;149(12):10041-10052. doi: 10.1007/s00432-023-04924-7. Epub 2023 Jun 1.

Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.对用于评估晚期非小细胞肺癌患者循环肿瘤 DNA 突变的定制 15 基因下一代测序 panel 的分析和临床验证。

PLoS One. 2022 Oct 18;17(10):e0276161. doi: 10.1371/journal.pone.0276161. eCollection 2022.

CPSF3 is a promising prognostic biomarker and predicts recurrence of non-small cell lung cancer.CPSF3是一种很有前景的预后生物标志物，可预测非小细胞肺癌的复发。

Oncol Lett. 2019 Sep;18(3):2835-2844. doi: 10.3892/ol.2019.10659. Epub 2019 Jul 24.

High Expression Independently Predicts Poor Prognosis for Lung Adenocarcinoma Patients.高表达独立预测肺腺癌患者预后不良。

Genes (Basel). 2019 Jan 10;10(1):36. doi: 10.3390/genes10010036.

TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.在肺癌中，当TP53突变与ALK重排同时出现时，具有预测和预后价值。

Ann Oncol. 2018 Oct 1;29(10):2028-2030. doi: 10.1093/annonc/mdy339.

Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.异常 S100A16 表达可能是非小细胞肺腺癌不良生存的独立预后指标。

PLoS One. 2018 May 10;13(5):e0197402. doi: 10.1371/journal.pone.0197402. eCollection 2018.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验